Sepsis - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 278 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 6, 1, 60, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 7 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Sepsis - Overview 10
Sepsis - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 17
Products under Development by Companies 20
Products under Development by Universities/Institutes 25
Sepsis - Therapeutics Assessment 28
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Sepsis - Companies Involved in Therapeutics Development 38
Adrenomed AG 38
Altor BioScience Corp 38
Am-Pharma BV 39
Arch Biopartners Inc. 39
Aridis Pharmaceuticals LLC 40
Asahi Kasei Pharma Corp 40
Astellas Pharma Inc 41
Batu Biologics Inc 41
Biomedica Management Corp 42
Boehringer Ingelheim GmbH 42
Bristol-Myers Squibb Company 43
Cell2B Advanced Therapeutics SA 43
Chiome Bioscience Inc 44
Cilian AG 44
Dr. Franz Kohler Chemie GmbH 45
Endacea Inc 45
Evec Inc 46
Ferring International Center SA 46
Huons Co Ltd 47
Immune Response BioPharma Inc 47
Immunethep SA 48
InflaRx GmbH 48
Inotrem SA 49
Integrated BioTherapeutics Inc 49
Lead Discovery Center GmbH 50
Leading BioSciences Inc 50
Lixte Biotechnology Holdings Inc 51
Merck & Co Inc 51
Navigen Pharmaceuticals Inc 52
Nohla Therapeutics Inc 52
Novartis AG 53
OncoImmune Inc 53
Ono Pharmaceutical Co Ltd 54
Opsona Therapeutics Ltd 54
Peptinov SAS 55
ProThera Biologics Inc 55
Ra Pharmaceuticals Inc 56
Recce Ltd 56
Revimmune LLC 57
Ribomic Inc 57
SciClone Pharmaceuticals Inc 58
SetLance srl 58
Shionogi & Co Ltd 59
Silence Therapeutics Plc 59
SK Biopharmaceuticals Co Ltd 60
Spider Biotech 60
Stemedica Cell Technologies Inc 61
Syntiron LLC 61
TaiRx Inc 62
Takeda Pharmaceutical Company Ltd 62
Therakind Ltd 63
Therashock LLC 63
TiGenix NV 64
VBS Pharmaceuticals 64
Sepsis - Drug Profiles 65
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 65
3K3A-APC - Drug Profile 66
7-H9 - Drug Profile 68
AB-012 - Drug Profile 69
AB-022 - Drug Profile 70
AcPepA - Drug Profile 71
adrecizumab - Drug Profile 72
ALT-836 - Drug Profile 73
AM-12 - Drug Profile 75
AM/AMBP-1 - Drug Profile 76
Aspidasept - Drug Profile 77
Atu-111 - Drug Profile 78
AyuV-25 - Drug Profile 79
BC-1215 - Drug Profile 80
BI-113823 - Drug Profile 81
Biologic to Inhibit PD-L1 for Immunology - Drug Profile 82
BMS-936559 - Drug Profile 83
BMS-986189 - Drug Profile 86
BRL-44408 - Drug Profile 87
C-23 - Drug Profile 88
CAR Peptide - Drug Profile 89
cefiderocol - Drug Profile 90
ceftaroline fosamil - Drug Profile 92
Cell Therapy for Sepsis - Drug Profile 95
Cx-611 - Drug Profile 96
CYT-107 - Drug Profile 100
Drug for Sepsis and Septic Shock - Drug Profile 103
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 104
EC-18 - Drug Profile 105
Escherichia coli vaccine - Drug Profile 107
ethinylestradiol - Drug Profile 108
EV-007156 - Drug Profile 109
Gamma-PN - Drug Profile 110
Glyco-23 - Drug Profile 111
HBN-1 - Drug Profile 112
HBN-3 - Drug Profile 113
HBN-4 - Drug Profile 114
HU-003 - Drug Profile 115
IFX-1 - Drug Profile 116
ImmStem - Drug Profile 118
ImmuneSafe - Drug Profile 119
IMT-504 - Drug Profile 120
IR-999 - Drug Profile 122
Klebsiella pneumoniae vaccine - Drug Profile 123
L-257 - Drug Profile 124
L-971 - Drug Profile 125
LB-100 - Drug Profile 127
lodelcizumab - Drug Profile 130
M-33 - Drug Profile 131
M-6229 - Drug Profile 133
melatonin - Drug Profile 134
Metablok - Drug Profile 135
Monoclonal Antibodies for Sepsis - Drug Profile 136
Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile 137
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 138
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 139
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 140
Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 141
Monoclonal Antibody to Inhibit Semaphorin 3A for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 142
Motrem - Drug Profile 143
MSP-68 - Drug Profile 144
NAV-838 - Drug Profile 145
nivolumab - Drug Profile 146
NOXD-21 - Drug Profile 185
OPN-305 - Drug Profile 186
OTP-300 - Drug Profile 189
OTP-602 - Drug Profile 190
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 191
physostigmine salicylate - Drug Profile 192
pneumococcal vaccine - Drug Profile 193
PNV-1 - Drug Profile 194
Protein to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 195
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 196
R-190 - Drug Profile 198
RA-101295 - Drug Profile 200
RBM-005 - Drug Profile 201
RECCE-327 - Drug Profile 202
Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile 204
Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile 205
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 209
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 210
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 211
Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile 212
Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 213
Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 214
Recombinant Protein to Target Von Willebrand Factor Type A1 Domain for Sepsis - Drug Profile 215
SAN-101 - Drug Profile 216
SB-056 - Drug Profile 217
selepressin - Drug Profile 218
Slit-2N - Drug Profile 219
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 221
Small Molecule to HDAC6 for Sepsis - Drug Profile 222
Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 223
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 224
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 225
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 226
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 227
Small Molecules to Inhibit Sialidase for Bacterial Sepsis - Drug Profile 228
SP-14 - Drug Profile 229
SP-9 - Drug Profile 230
Staphylococcus aureus (multivalent) vaccine - Drug Profile 231
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 232
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 234
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 240
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 241
Synthetic Peptides for Infectious Disease - Drug Profile 242
Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 243
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 244
TF-0003 - Drug Profile 245
thrombomodulin alfa - Drug Profile 246
thymalfasin - Drug Profile 248
tosatoxumab - Drug Profile 249
tranexamic acid - Drug Profile 251
TRX-306 - Drug Profile 253
vancomycin hydrochloride - Drug Profile 254
Yersinia pestis vaccine - Drug Profile 255
Sepsis - Dormant Projects 256
Sepsis - Discontinued Products 260
Sepsis - Product Development Milestones 262
Featured News & Press Releases 262
Appendix 269
Methodology 269
Coverage 269
Secondary Research 269
Primary Research 269
Expert Panel Validation 269
Contact Us 269
Disclaimer 270

List of Tables

Number of Products under Development for Sepsis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Sepsis - Pipeline by Adrenomed AG, H1 2017
Sepsis - Pipeline by Altor BioScience Corp, H1 2017
Sepsis - Pipeline by Am-Pharma BV, H1 2017
Sepsis - Pipeline by Arch Biopartners Inc., H1 2017
Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Sepsis - Pipeline by Astellas Pharma Inc, H1 2017
Sepsis - Pipeline by Batu Biologics Inc, H1 2017
Sepsis - Pipeline by Biomedica Management Corp, H1 2017
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Sepsis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
Sepsis - Pipeline by Chiome Bioscience Inc, H1 2017
Sepsis - Pipeline by Cilian AG, H1 2017
Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2017
Sepsis - Pipeline by Endacea Inc, H1 2017
Sepsis - Pipeline by Evec Inc, H1 2017
Sepsis - Pipeline by Ferring International Center SA, H1 2017
Sepsis - Pipeline by Huons Co Ltd, H1 2017
Sepsis - Pipeline by Immune Response BioPharma Inc, H1 2017
Sepsis - Pipeline by Immunethep SA, H1 2017
Sepsis - Pipeline by InflaRx GmbH, H1 2017
Sepsis - Pipeline by Inotrem SA, H1 2017
Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1 2017
Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2017
Sepsis - Pipeline by Leading BioSciences Inc, H1 2017
Sepsis - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Sepsis - Pipeline by Merck & Co Inc, H1 2017
Sepsis - Pipeline by Navigen Pharmaceuticals Inc, H1 2017
Sepsis - Pipeline by Nohla Therapeutics Inc, H1 2017
Sepsis - Pipeline by Novartis AG, H1 2017
Sepsis - Pipeline by OncoImmune Inc, H1 2017
Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Sepsis - Pipeline by Opsona Therapeutics Ltd, H1 2017
Sepsis - Pipeline by Peptinov SAS, H1 2017
Sepsis - Pipeline by ProThera Biologics Inc, H1 2017
Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
Sepsis - Pipeline by Recce Ltd, H1 2017
Sepsis - Pipeline by Revimmune LLC, H1 2017
Sepsis - Pipeline by Ribomic Inc, H1 2017
Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1 2017
Sepsis - Pipeline by SetLance srl, H1 2017
Sepsis - Pipeline by Shionogi & Co Ltd, H1 2017
Sepsis - Pipeline by Silence Therapeutics Plc, H1 2017
Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Sepsis - Pipeline by Spider Biotech, H1 2017
Sepsis - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Sepsis - Pipeline by Syntiron LLC, H1 2017
Sepsis - Pipeline by TaiRx Inc, H1 2017
Sepsis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Sepsis - Pipeline by Therakind Ltd, H1 2017
Sepsis - Pipeline by Therashock LLC, H1 2017
Sepsis - Pipeline by TiGenix NV, H1 2017
Sepsis - Pipeline by VBS Pharmaceuticals, H1 2017
Sepsis - Dormant Projects, H1 2017
Sepsis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Sepsis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Sepsis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Sepsis - Discontinued Products, H1 2017
Sepsis - Discontinued Products, H1 2017 (Contd..1), H1 2017